Compare RCS & SMTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RCS | SMTI |
|---|---|---|
| Founded | 1994 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 251.8M | 208.8M |
| IPO Year | N/A | 2008 |
| Metric | RCS | SMTI |
|---|---|---|
| Price | $5.50 | $21.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $34.00 |
| AVG Volume (30 Days) | ★ 143.5K | 40.8K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 10.12% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | N/A | ★ $15,586,976.00 |
| Revenue This Year | N/A | $17.31 |
| Revenue Next Year | N/A | $12.48 |
| P/E Ratio | ★ N/A | $419.40 |
| Revenue Growth | N/A | ★ 32.47 |
| 52 Week Low | $5.09 | $16.05 |
| 52 Week High | $8.00 | $35.70 |
| Indicator | RCS | SMTI |
|---|---|---|
| Relative Strength Index (RSI) | 52.43 | 53.38 |
| Support Level | $5.36 | $18.20 |
| Resistance Level | $5.68 | $24.17 |
| Average True Range (ATR) | 0.12 | 1.21 |
| MACD | 0.01 | -0.22 |
| Stochastic Oscillator | 53.85 | 34.93 |
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with the objective.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.